Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway
Open Access
- 17 March 2023
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 30 (7) , 973-984
Abstract
The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8, an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S100A8 competitive inhibitory peptide (divalent peptide3A5) against TLR4/MD-2, using the alanine scanning. Divalent peptide3A5 suppressed S100A8-mediated interleukin-8 and vascular endothelial growth factor production in human colorectal tumor SW480 cells. Using SW480-transplanted xenograft models, divalent peptide3A5 suppressed tumor progression in a dose-dependent manner. We demonstrated that combination therapy with divalent peptide3A5 and bevacizumab synergistically suppressed tumor growth in SW480 xenograft models. Using syngeneic mouse models, we found that divalent peptide3A5 improved the efficacy of anti-programmed death (PD)1 antibody, and lung metastasis. In addition, by using multivalent peptide library screening based on peptide3A5, we then isolated two more candidates; divalent ILVIK, and tetravalent ILVIK. Of note, multivalent ILVIK, but not monovalent ILVIK showed competitive inhibitory activity against TLR4/MD-2 complex, and anti-tumoral activity in SW480 xenograft models. As most tumor cells including SW480 cells also express TLR4, S100A8 inhibitory peptides would target both the tumor microenvironment and tumor cells. Thus, multivalent S100A8 inhibitory peptides would provide new pharmaceutical options for aggressive cancers.Keywords
All Related Versions
Funding Information
- MEXT | Japan Society for the Promotion of Science (JP18K07245, JP21K07157, JP19H03506)
- Takeda Science Foundation
- Astellas Foundation for Research on Metabolic Disorders
- Japan Agency for Medical Research and Development (JP21cm0106281)
This publication has 42 references indexed in Scilit:
- Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2Proceedings of the National Academy of Sciences, 2012
- Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patientsLeukemia, 2010
- A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine releaseProceedings of the National Academy of Sciences, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complexNature, 2009
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinJournal of Experimental Medicine, 2008
- Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasisNature Cell Biology, 2006
- The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophagesJournal of Clinical Investigation, 2005
- Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2Science, 2002
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889